Evidence map›Paper›PMID 40189674›Full record

ArticleAnnals of surgical oncology2025

Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy in Cytoreductive Surgery for Advanced-Stage Ovarian Cancer.

Adrian Kohut, Matthew L Anderson, Vaagn Andikyan, Maya Yasukawa, Lindsey Nguy, Andreas Karachristos, Timothy Nywening, Gil Mor, Radhika Gogoi, Joshua G Cohen and 2 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Adrian KohutDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of South Florida Morsani College of Medicine, Tampa, FL, USA. akohut@usf.edu.ORCID http://orcid.org/0009-0000-5016-8838
Matthew L AndersonDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Vaagn AndikyanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Maya YasukawaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Lindsey NguyDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Andreas KarachristosDivision of Surgical Oncology, Department of Surgery, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Timothy NyweningDivision of Surgical Oncology, Department of Surgery, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Gil MorDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mott Center for Human Growth and Development, Wayne State University School of Medicine, Detroit, MI, USA.
Radhika GogoiDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mott Center for Human Growth and Development, Wayne State University School of Medicine, Detroit, MI, USA.
Joshua G CohenDivision of Gynecologic Oncology, Department of Surgery, City of Hope Orange County Lennar Foundation Cancer Center, Irvine, CA, USA.
Jeff F LinDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY, USA.
Thomas J RutherfordDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of South Florida Morsani College of Medicine, Tampa, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperthermic intraperitoneal chemotherapy (HIPEC) is used to eliminate minimal residual disease in patients with peritoneal surface malignancies, including advanced epithelial ovarian cancer (EOC). While some trials suggest potential benefits, the role of HIPEC during cytoreductive surgery (CRS) in EOC remains uncertain. This study aimed to evaluate outcomes for patients undergoing HIPEC during CRS for advanced-stage EOC in the United States (US).

methodsThis multicenter, retrospective cohort study included women with stage III-IV EOC who underwent CRS with or without HIPEC between 2006 and 2021 at Commission on Cancer-accredited US facilities. Propensity score matching was used to create a control group of patients who underwent CRS only. Overall survival (OS) was analyzed using the Kaplan-Meier log-rank method and adjusted for confounding factors with Cox proportional hazards regression.

resultsAmong 1400 patients identified, 700 underwent CRS with HIPEC and 700 underwent CRS only. Of these 1400 patients, 932 underwent interval CRS and 468 underwent primary CRS. No significant difference in median OS was observed between the overall CRS+HIPEC and CRS-only groups (57.6 vs. 47.6 months; p = 0.105). However, interval CRS+HIPEC was associated with significantly improved median OS compared with interval CRS-only (57.6 vs. 45.7 months; p = 0.003). After adjustment, HIPEC remained significantly associated with improved survival (hazard ratio 0.77, 95% confidence interval 0.64-0.92; p = 0.004).

conclusionsHIPEC is associated with improved OS in patients undergoing interval CRS for advanced-stage EOC. Further research should explore the selective use of HIPEC during interval CRS.

Indexed as

Carcinoma, Ovarian EpithelialCytoreduction Surgical ProceduresHyperthermia, InducedHyperthermic Intraperitoneal ChemotherapyOvarian NeoplasmsPeritoneal NeoplasmsAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesCytoreductive surgeryHyperthermic intraperitoneal chemotherapyNational cancer databaseNeoadjuvant chemotherapyOvarian cancerPeritoneal surface malignancies

Identifiers

PMID40189674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.